Skip to content

United Therapeutics UTHR Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$1.29B+6.3%$1.33B+11.7%$1.27B+14.5%$1.24B+16.1%$1.21B+15.2%
$88.4M+14.4%$85.6M+18.1%$82.5M+24.1%$79.7M+31.3%$77.3M+40.8%
$149.8M-0.3%$147.7M+2.6%$135.7M+1.6%$138.3M+22.4%$150.2M+94.8%
$1.56B+10.7%$1.56B+17.6%$1.56B+36.9%$1.37B+24.0%$1.41B+44.1%
$546.4M+92.9%$520.5M+111%$434.3M+82.1%$300.3M+31.9%$283.2M+24.6%
$2.5B$1B
$700M+133%$400M+100%
-$2.64B-840%-$1.25B+0.5%-$1.32B-3.9%-$431.2M+64.1%-$280.6M+75.1%
-$213.8M-148%$237.4M-17.7%$648.4M
$1.02B-9.9%$1.04B-3.7%$1.12B+24.9%$1.07B+22.0%$1.13B+50.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does United Therapeutics generate?
United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
What is United Therapeutics's free cash flow?
After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
Where does United Therapeutics's cash flow data come from?
Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.